Skip to nav Skip to content

Journal Club

September 15, 2021

 All Issues
 Read the last Journal Club Read the next Journal Club 

Journal Club

Double Up! Revaccination Strategies for HIV-infected Hepatitis B Vaccine Nonresponders

By Christopher J. Graber, MD, MPH, FIDSA

Lack of a fully protective antibody response to a standard hepatitis B vaccination series is common, especially among HIV-infected individuals. Many strategies have emerged to revaccinate nonresponders, but few have been rigorously evaluated.

The authors of a recent study in JAMA Network Open randomized 107 HIV-infected individuals in Chile who had hepatitis B surface antibody (anti-HBs) titers less than 10 IU/mL after an initial HBV vaccination regimen to receive either a high-dose regimen of 40 µg of the ENGERIX-B recombinant vaccine at 0, 1, and 2 months or a standard 20 µg dose at 0, 1, and 2 months and determined serologic response (anti-HBs > 10 IU/mL) 4 to 8 weeks after series completion. Those who achieved adequate serologic response also had titers measured 1 year after completing the final dose.

The majority of patients had stable HIV disease (98% were receiving antiretroviral therapy, mean CD4 count 418 cells/mm3, 86% with undetectable viral load); mean age was 47 years, and 76% were men. Mean time between the last dose of the initial vaccination series and the first dose of the intervention series was 4.5 months. Serologic response 4 to 8 weeks after series completion was significantly higher in the high-dose group (72% vs. 51%; odds ratio, 2.48 [95% confidence interval, 1.02-6.10; P = .03]) with significantly higher quantitative anti-HBs titers (398 vs. 159 IU/mL, P < .001). Among patients who completed 1-year follow-up, 80% of patients in the high-dose group had persistent serologic response as compared to 39% in the standard-dose group (P = .01).

The robust response seen with this rapid interval high-dose revaccination strategy is welcome news to providers who commonly encounter HBV vaccine nonresponse in HIV-infected patients.

(Vargas et al. JAMA Netw Open 2021;4(8):e2120929.)

This website uses cookies

We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable social media functionality.